(TheNewswire)
LONDON, ONTARIO – TheNewswire - April 28, 2021 – Sernova Corp. (TSXV:SVA)(OTC:SEOVF) (FSE/XETRA:PSH ), a leading clinical-stageregenerative medicine therapeutics company, announced today thehighlights of its first virtual Key Opinion Leader (KOL) event onthyroid disease.
The KOL event featured a presentation by Dr. SamWiseman, a leading surgeon and internationally recognized expert inthe management of thyroid and parathyroid disease. In hispresentation, Dr. Wiseman discussed current treatment options and thepotential for a novel cell therapy approach for the treatment ofpostoperative hypothyroidism using Sernova’s Cell Pouch™. Thepresentation was followed by a Q&A session with attendees.
“I’m very excited about this program because assurgeons, we will be able to offer our patients a treatment optionthat could allow for avoidance of postoperative hypothyroidismrequiring life-long dependence on thyroid medication,” said Dr. SamWiseman. “Our preclinical study evaluating transplantation of humanthyroid tissue into Sernova’s Cell Pouch has shown promisingresults. I believe this very exciting new approach represents acritical step towards an entirely new treatment option forpost-thyroidectomy hypothyroidism."
Dr. Wiseman's presentation and the subsequent Q&Asession are now available on Sernova's website at www.sernova.com and on Sernova’ssocial media channels.
ABOUT SERNOVA'S THYROID PROGRAM
Sernova's approach for treating postoperativehypothyroidism is to transplant a portion of the thyroid gland beingremoved into a pre-implanted vascularized Cell Pouch™ to recoverthyroid function. In collaboration with Dr. Wiseman, preclinical proofof concept study conducted under a grant from the British ColumbiaTransplant Foundation is contributing to advancing Sernova's plans toconduct clinical assessment of this novel approach. Sernova'soverall treatment goal is to preserve thyroid function, and improvepatient quality of life, relative to current treatments.
Thyroidectomy is commonly performed for management ofcancer, and for treatment of benign (non-cancerous) disease thatincludes nodules, goitre and hyperthyroidism. It is estimated thatabout 150,000 thyroidectomies are performed in the US annually, withmost individuals undergoing thyroid surgery eventually being diagnosedwith benign conditions. Patients undergoing total thyroidectomy, andmany patients undergoing partial thyroidectomy, require life-long oralpostoperative thyroid hormone replacement.
Post-surgical thyroid hormone replacement therapy, ifmonitored carefully, can be effective; however, some patients maysuffer from deleterious side-effects including body weight gain,fatigue, and depression, with a resultant negative impact on qualityof life, and significant costs to the healthcare system. We believeSernova's development of new therapeutic strategies to treatpost-surgical hypothyroidism has the potential of addressing animportant unmet medical need.
ABOUT SERNOVA
Sernova is developing regenerative medicine therapeutic technologiesusing a medical device and immune protected therapeutic cells (i.e.human donor cells, corrected human cells, stem cell-derived cells andtissues) to improve the treatment and quality of life of people withchronic metabolic diseases such as insulin-dependent diabetes, blooddisorders including hemophilia, and other diseases treated throughreplacement of proteins or hormones missing or in short supply withinthe body. For more information, please visit www.sernova.com .
FOR FURTHER INFORMATION, PLEASECONTACT:
Dominic Gray
Sernova Corp.
Tel: (519) 858-5126
FORWARD-LOOKING INFORMATION
This release may contain forward-looking statements. Forward-lookingstatements are statements that are not historical facts and aregenerally, but not always, identified by the words"expects", "plans", "anticipates","believes", "intends", "estimates","projects", "potential" and similar expressions,or that events or conditions "will", "would","may", "could" or "should" occur.Although Sernova believes the expectations expressed in suchforward-looking statements are based on reasonable assumptions, suchstatements are not guarantees of future performance, and actualresults may differ materially from those in forward-lookingstatements. Forward-looking statements are based on the beliefs,estimates, and opinions of Sernova's management on the date suchstatements were made, which include our beliefs about the conduct andoutcome of clinical trials. Sernova expressly disclaims any intentionor obligation to update or revise any forward-looking statementswhether as a result of new information, future events or otherwise.
Copyright (c) 2021 TheNewswire - All rights reserved.